...
首页> 外文期刊>Indian journal of pharmaceutical sciences. >Influence of Formulation Factors and Compression Force on Release Profile of Sustained Release Metoprolol Tablets using Compritol (R) 888ATO as Lipid Excipient
【24h】

Influence of Formulation Factors and Compression Force on Release Profile of Sustained Release Metoprolol Tablets using Compritol (R) 888ATO as Lipid Excipient

机译:配制因子和压缩力对以Compritol(R)888ATO为脂质赋形剂的美托洛尔缓释片的释放特性的影响

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Tablets containing metoprolol succinate and Compritol (R) 888ATO in the ratio of 1: 2 yielded the desired sustained release profile in phosphate buffer pH 6.8 when evaluated using USP type II paddle apparatus and was selected as the optimized formulation. Robustness of optimized formulation was assessed by studying the effect of factors like varying source of metoprolol succinate and Compritol (R) 888ATO, compression force and hydroalcoholic dissolution medium on the release profile. No significant difference (P>0.05) in release profile was observed when metoprolol succinate from three different sources and Compritol (R) 888ATO from two different batches were used. Release profile of sustained release tablets of metoprolol succinate in media containing various concentrations of ethanol was comparable with media devoid of ethanol as evaluated by f2 test. This indicated that release profile of sustained release tablets of metoprolol succinate was reliable with no significant change due to variation in source of active pharmaceutical ingredient, particularly due to particle size distribution. Sustained release tablets of metoprolol succinate yielded release pattern within specifications irrespective of presence or absence of ethanol in the medium indicating that release properties of Compritol (R) 888ATO matrix are not affected by ethanol. Tablets compressed at compression force of <100 kg/cm(2) exhibited low hardness with total porosity of 15.39% and significantly increased (P<0.05) metoprolol succinate release as compared to tablets compressed at 2000 kg/cm(2) with 6.90% of total porosity revealing influence of compression force. Compritol (R) 888ATO holds great potential in providing reliable and controlled release profile of highly water soluble metoprolol succinate.
机译:当使用USP II型桨式装置进行评估时,含有美托洛尔琥珀酸酯和Compritol(R)888ATO比例为1:2的片剂在pH 6.8的磷酸盐缓冲液中可产生所需的缓释曲线,并被选作优化制剂。通过研究诸如美托洛尔琥珀酸和Compritol?888ATO的来源不同,压缩力和水醇溶出介质等因素对释放曲线的影响,评估了优化配方的稳健性。当使用来自三个不同来源的琥珀酸美托洛尔和使用来自两个不同批次的Compritol?888ATO时,释放曲线没有观察到显着差异(P> 0.05)。通过f2试验评估,琥珀酸美托洛尔缓释片在含有各种浓度乙醇的培养基中的释放曲线与不含乙醇的培养基中的释放曲线相当。这表明琥珀酸美托洛尔的缓释片剂的释放曲线是可靠的,并且由于活性药物成分的来源变化,特别是由于粒度分布,没有明显变化。不论介质中是否存在乙醇,琥珀酸美托洛尔的缓释片均在规格范围内产生释放模式,这表明Compritol(R)888ATO基质的释放特性不受乙醇影响。与以2000 kg / cm(2)压缩为6.90%的片剂相比,以<100 kg / cm(2)的压缩力压缩的片剂表现出低硬度,总孔隙率为15.39%,并显着增加(P <0.05)琥珀酸美托洛尔的释放。总孔隙率揭示了压缩力的影响。 Compritol(R)888ATO在提供高度水溶性的琥珀酸美托洛尔的可靠和控释特性方面具有巨大潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号